Plus Therapeutics Stock Return On Asset
| PSTV Stock | USD 1.31 0.04 2.96% |
Plus Therapeutics fundamentals help investors to digest information that contributes to Plus Therapeutics' financial success or failures. It also enables traders to predict the movement of Plus Stock. The fundamental analysis module provides a way to measure Plus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Plus Therapeutics stock.
Return On Assets is likely to drop to -1.23 in 2024. Plus | Return On Asset |
Plus Therapeutics Company Return On Asset Analysis
Plus Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Plus Therapeutics Return On Asset | -0.69 |
Most of Plus Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Plus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Plus Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Plus Therapeutics is extremely important. It helps to project a fair market value of Plus Stock properly, considering its historical fundamentals such as Return On Asset. Since Plus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Plus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Plus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Plus Total Assets
Total Assets |
|
Based on the latest financial disclosure, Plus Therapeutics has a Return On Asset of -0.6939. This is 92.07% lower than that of the Biotechnology sector and 97.06% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Plus Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Plus Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Plus Therapeutics could also be used in its relative valuation, which is a method of valuing Plus Therapeutics by comparing valuation metrics of similar companies.Plus Therapeutics is currently under evaluation in return on asset category among its peers.
Plus Fundamentals
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 | ||||
| Profit Margin | (2.40) % | ||||
| Operating Margin | (2.89) % | ||||
| Current Valuation | 6.57 M | ||||
| Shares Outstanding | 5.9 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 11.30 % | ||||
| Number Of Shares Shorted | 103.98 K | ||||
| Price To Book | 3.76 X | ||||
| Price To Sales | 1.44 X | ||||
| Revenue | 4.91 M | ||||
| Gross Profit | (9.47 M) | ||||
| EBITDA | (12.69 M) | ||||
| Net Income | (13.32 M) | ||||
| Cash And Equivalents | 20.27 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 4.18 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 2.81 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (12.85 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | (2.37) X | ||||
| Target Price | 15.75 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 7.96 M | ||||
| Total Asset | 11.39 M | ||||
| Retained Earnings | (480.5 M) | ||||
| Working Capital | (893 K) | ||||
| Net Asset | 11.39 M |
About Plus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Plus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.